{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:17:29Z","timestamp":1791065849715,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.2515\/therapie\/2011036","type":"journal-article","created":{"date-parts":[[2011,8,8]],"date-time":"2011-08-08T10:43:40Z","timestamp":1312800220000},"page":"221-230","source":"Crossref","is-referenced-by-count":7,"title":["Niveau de preuve du suivi therapeutique pharmacologique de la ribavirine"],"prefix":"10.1016","volume":"66","author":[{"given":"Caroline","family":"Solas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Par\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Quaranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Stanke-Labesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2011036_bb0005","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2011036_bb0010","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.2515\/therapie\/2011036_bb0015","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"key":"10.2515\/therapie\/2011036_bb0020","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/hep.21853","article-title":"Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response","volume":"46","author":"Feld","year":"2007","journal-title":"Hepatology"},{"key":"10.2515\/therapie\/2011036_bb0025","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapyenhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"10.2515\/therapie\/2011036_bb0030","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1067\/mcp.2002.127112","article-title":"Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models","volume":"72","author":"Jen","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.2515\/therapie\/2011036_bb0035","first-page":"21","article-title":"Evidence-based therapeutic drug monitoring","volume":"23","author":"Le Guellec","year":"2009","journal-title":"La lettre du Pharmacologue"},{"issue":"2","key":"10.2515\/therapie\/2011036_bb0040","first-page":"105","article-title":"The relationship between serum ribavirin concentration and early virological response is limited to slow viral kinetic responders to combination peg interferon alpha 2a (40 Kd) plus ribavirin therapy in patients with genotype 1-4 HCV","volume":"20","author":"Stanke-Labesque","year":"2006","journal-title":"Fundam Clin Pharmacol"},{"key":"10.2515\/therapie\/2011036_bb0045","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000090942","article-title":"Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy","volume":"76","author":"Donnerer","year":"2006","journal-title":"Pharmacology"},{"key":"10.2515\/therapie\/2011036_bb0050","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/hep.22217","article-title":"Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C","volume":"47","author":"Loustaud-Ratti","year":"2008","journal-title":"Hepatology"},{"key":"10.2515\/therapie\/2011036_bb0055","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/01.qai.0000170034.90438.68","article-title":"Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV\/hepatitis C virus-coinfected patients","volume":"39","author":"Rendon","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.2515\/therapie\/2011036_bb0060","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00007691-200010000-00010","article-title":"Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C","volume":"22","author":"Jen","year":"2000","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2011036_bb0065","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1128\/AAC.47.1.124-129.2003","article-title":"Ribavirin quantification in combination treatment of chronic hepatitis C","volume":"47","author":"Larrat","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011036_bb0070","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1046\/j.1365-2125.2003.01780.x","article-title":"Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection","volume":"55","author":"Tsubota","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011036_bb0075","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/135965350801300401","article-title":"Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients","volume":"13","author":"Maynard","year":"2008","journal-title":"Antivir Ther"},{"key":"10.2515\/therapie\/2011036_bb0080","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000081741","article-title":"Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C","volume":"48","author":"Arase","year":"2005","journal-title":"Intervirology"},{"key":"10.2515\/therapie\/2011036_bb0085","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hep.20563","article-title":"High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C","volume":"41","author":"Lindahl","year":"2005","journal-title":"Hepatology"},{"key":"10.2515\/therapie\/2011036_bb0090","series-title":"Ribavirin concentration at week four is an independent predictor for sustained viral response after treatment of hepatitis C genotype 2\/3 (Nordynamic Trial)","author":"Christensen","year":"2008"},{"key":"10.2515\/therapie\/2011036_bb0095","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/jmv.21227","article-title":"Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV","volume":"80","author":"Nicot","year":"2008","journal-title":"J Med Virol"},{"issue":"4","key":"10.2515\/therapie\/2011036_bb0100","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/jac\/dkn013","article-title":"Gonzalez de Requena D, Bonora S, et al. The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV\/HCV-co-infected patients treated with ribavirin and pegylated interferon","volume":"61","author":"Aguilar Marucco","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.2515\/therapie\/2011036_bb0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jhep.2007.01.027","article-title":"Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV\/HCV co-infected patients during treatment with pegylated interferon and ribavirin","volume":"47","author":"Dahari","year":"2007","journal-title":"J Hepatol"},{"issue":"4","key":"10.2515\/therapie\/2011036_bb0110","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1128\/AAC.01399-09","article-title":"Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV coinfected patients treated for chronic hepatitis C","volume":"54","author":"Morello","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011036_bb0115","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s10238-005-0085-0","article-title":"Changes in serum and red blood cell membrane lipids in patients treated with interferon ribavirin for chronic hepatitis C","volume":"5","author":"Tanaka","year":"2005","journal-title":"Clin Exp Med"},{"key":"10.2515\/therapie\/2011036_bb0120","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2893.2004.00490.x","article-title":"Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection","volume":"11","author":"Sulkowski","year":"2004","journal-title":"J Viral Hepat"},{"key":"10.2515\/therapie\/2011036_bb0125","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1542-3565(04)00064-3","article-title":"Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia","volume":"2","author":"Homma","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.2515\/therapie\/2011036_bb0130","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1365-2893.2003.00475.x","article-title":"Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia","volume":"11","author":"Lindhal","year":"2004","journal-title":"J Viral Hepat"},{"issue":"6","key":"10.2515\/therapie\/2011036_bb0135","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2133\/dmpk.19.438","article-title":"Assessment of adverse reactions and pharmacokinetics of ribavirin in combination with interferon alpha-2b in patients with chronic hepatitis C","volume":"19","author":"Uchida","year":"2004","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.2515\/therapie\/2011036_bb0140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.hepres.2005.10.003","article-title":"Erythrocyte ribavirin concentration for assessing haemoglobin reduction in interferon and ribavirin combination therapy","volume":"34","author":"Inoue","year":"2006","journal-title":"Hepatol Res"},{"issue":"Suppl. 1","key":"10.2515\/therapie\/2011036_bb0145","first-page":"17","article-title":"The clinical pharmacology of ribavirin","volume":"19","author":"Glue","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.2515\/therapie\/2011036_bb0150","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1365-2125.2006.02704.x","article-title":"Pharmacokinetics of ribavirin in patients with hepatitis C virus","volume":"62","author":"Wade","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011036_bb0155","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/clinids\/12.6.1139","article-title":"Molecular mechanisms of action of ribavirin","volume":"12","author":"Patterson","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.2515\/therapie\/2011036_bb0160","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/00007691-200212000-00004","article-title":"Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis","volume":"24","author":"Bruchfeld","year":"2002","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2011036_bb0165","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2893.2008.01004.x","article-title":"Correlation of serum ribavirin concentration with pretreatment renal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin","volume":"15","author":"Toyoda","year":"2008","journal-title":"J Virol Hepat"},{"key":"10.2515\/therapie\/2011036_bb0170","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/ndt\/gfm724","article-title":"Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C","volume":"23","author":"Van Leusen","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.2515\/therapie\/2011036_bb0175","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jhep.2006.12.016","article-title":"The treatment of chronic hepatitis C with peginterferon alfa-2 (40kDa) plus ribavirin in haemodialysed patients awaiting renal transplant","volume":"46","author":"Rendina","year":"2007","journal-title":"J Hepatol"},{"key":"10.2515\/therapie\/2011036_bb0180","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1046\/j.1365-2125.2000.00186.x","article-title":"The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease","volume":"49","author":"Glue","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011036_bb0185","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2893.2006.00720.x","article-title":"Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation","volume":"13","author":"Dumortier","year":"2006","journal-title":"J Viral Hepat"},{"issue":"7287","key":"10.2515\/therapie\/2011036_bb0190","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature08825","article-title":"ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C","volume":"464","author":"Fellay","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.2515\/therapie\/2011036_bb0195","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1053\/j.gastro.2010.06.016","article-title":"Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"issue":"4","key":"10.2515\/therapie\/2011036_bb0200","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1053\/j.gastro.2010.06.071","article-title":"ITPA polymorphism affects ribavirininduced anemia and outcomes of therapy\u2013a genome-wide study of Japanese HCV virus patients","volume":"139","author":"Ochi","year":"2010","journal-title":"Gastroenterology"},{"issue":"11","key":"10.2515\/therapie\/2011036_bb0205","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1872-034X.2010.00741.x","article-title":"ITPA gene variant protects against anemia induced by pegylated interferon-\u03b1 and ribavirin therapy for Japanese patients with chronic hepatitis C","volume":"40","author":"Sakamoto","year":"2010","journal-title":"Hepatol Res"},{"key":"10.2515\/therapie\/2011036_bb0210","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jpba.2007.06.004","article-title":"Ribavirin: analytical determinations since the origin until today","volume":"45","author":"Bosch","year":"2007","journal-title":"J Pharm Biomed Anal"},{"key":"10.2515\/therapie\/2011036_bb0215","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1128\/AAC.24.5.696","article-title":"Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin","volume":"24","author":"Austin","year":"1983","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.2515\/therapie\/2011036_bb0220","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.43.11.2716","article-title":"High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes","volume":"43","author":"Homma","year":"1999","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.2515\/therapie\/2011036_bb0225","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/FTD.0b013e31815bddf3","article-title":"Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C","volume":"29","author":"Morello","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2011036_bb0230","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jchromb.2006.03.019","article-title":"Validation of liquid\/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients","volume":"835","author":"D\u2019Avolio","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.2515\/therapie\/2011036_bb0235","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jchromb.2005.12.034","article-title":"Sensitive and specific LC-MS\/MS method for the simultaneous measurements of viramidine and ribavirin in human plasma","volume":"832","author":"Liu","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"Suppl. 1","key":"10.2515\/therapie\/2011036_bb0240","first-page":"84","article-title":"A sensitive and specific method for the quantification of ribavirin in humanplasma by high performance chromatography-tandem mass spectrometry","volume":"22","author":"Jourdil","year":"2008","journal-title":"Fundam Clin Pharmacol"},{"key":"10.2515\/therapie\/2011036_bb0245","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/FTD.0b013e3181a665e3","article-title":"Feasibility of ribavirin therapeutic drug monitoring in hepatitis C","volume":"31","author":"Sauvage","year":"2009","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2011036_bb0250","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1177\/135965350701200815","article-title":"Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIVcoinfected patients","volume":"12","author":"Crespo","year":"2007","journal-title":"Antivir Ther"},{"key":"10.2515\/therapie\/2011036_bb0255","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1128\/AAC.48.10.3813-3816.2004","article-title":"Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood","volume":"48","author":"Inoue","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.2515\/therapie\/2011036_bb0260","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/FTD.0b013e3181d3f686","article-title":"Stability of ribavirin concentrations depending on the type of blood collection tube and preanalytical conditions","volume":"32","author":"Marquet","year":"2010","journal-title":"Ther Drug Monit"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T16:25:21Z","timestamp":1686241521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716307715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0040595716307715"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2011036","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}